IMUNON Reports Positive Phase 2 MRD Clinical Data for IMNN‑001 in Frontline Ovarian Cancer, Overcoming Historical IL‑12 Safety Barriers

IMUNON recently reported positive Phase 2 minimal residual disease (MRD) clinical data for its IL‑12 DNA immunotherapy, IMNN‑001, in newly diagnosed advanced ovarian cancer.

The data show that IMNN‑001, delivered intraperitoneally with standard neoadjuvant/adjuvant chemotherapy plus bevacizumab, led to a lower MRD‑positive rate (44% vs 67%), a higher circulating tumor DNA clearance rate (87.5% vs 62.5%), and a numerically higher rate of patients achieving no evidence of disease after frontline therapy (100% vs 56%).

The trial demonstrated a highly favorable safety and tolerability profile:
no cytokine release syndrome, systemic toxicities, or serious immune‑related adverse events have been observed to date, which the company highlights as overcoming historical IL‑12 safety barriers.

These MRD findings complement prior Phase 2 OVATION 2 results, where IMNN‑001 plus chemotherapy was associated with a median overall survival of 45.1 vs 30.4 months, and 65.6 vs 41.4 months in patients also receiving PARP inhibitor maintenance therapy.

IMNN‑001 is under Phase 3 development and is being evaluated as a front‑line treatment for advanced epithelial ovarian cancer, with the goal of moving toward a potential regulatory submission.